38 Grants (Page 1 of 2)
2022
Bacterial Targets of T3SS Effector Proteases
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R03AI165428-01), $72,305USD, 2022-04-22 -- 2024-03-31
 
T3SS Effector Regulation of Bacterial Metabolism
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R21AI168453-01), $186,498USD, 2022-04-22 -- 2024-03-31
2021
Molecular and Cellular Biology Core
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM130448-02-7578), $270,638USD, 2020-06-01 -- 2025-04-30
2020
Developing Bacterial Glycosyltransferase Inhibitors as Anti-Virulence Drugs
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R56AI153202-01), $614,542USD, 2020-09-01 -- 2021-08-31
 
Molecular and Cellular Biology Core
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 1P20GM130448-01A1-7578), $286,978USD, 2020
2018
Functions of Translocated Bacterial Glycosyltransferases
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R21AI127973-02), $225,000USD, 12/07/2016 -- 11/30/2018
 
Using anti-inflammatory bacterial proteins to treat psoriasis
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skin Diseases (NIAMS) (ID: 1R56AR072594-01A1), $281,593USD, 09/13/2018 -- 08/31/2019
2017
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI099002-05), $375,000USD, 01/11/2013 -- 12/31/2017
 
Functions of Translocated Bacterial Glycosyltransferases
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R21AI127973-01), $187,500USD, 12/07/2016 -- 11/30/2018
2016
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 4R01AI099002-04), $375,000USD, 01/11/2013 -- 12/31/2017
2015
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R21AI101231-02), $225,000USD, 08/01/2014 -- 07/31/2016
 
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI099002-03), $375,000USD, 01/11/2013 -- 12/31/2017
2014
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R21AI101231-01A1), $187,500USD, 08/01/2014 -- 07/31/2016
 
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI099002-02), $375,000USD, 01/11/2013 -- 12/31/2017
2013
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI099002-01A1), $88,125USD, 01/11/2013 -- 12/31/2017
 
Reverse vaccinology of enterotoxigenic E. coli
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R21AI092266-03), $211,500USD, 08/01/2012 -- 07/31/2015
2012
Bacterial effector inhibition of type I interferon
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 7R21AI093913-03), $158,452USD, 03/01/2011 -- 02/28/2014
 
Bacterial effector inhibition of type I interferon
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R21AI093913-02), $29,048USD, 03/01/2011 -- 09/30/2012
 
Bacterial effectors targeting the IKK/NF-kB pathway
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 7R56AI099002-02), $375,000USD, 09/04/2012 -- 01/10/2013
 
Delivery of a bacterial inhibitor of NF-kB to colon tumors
Hardwidge, Philip R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R03CA155868-02), $8,341USD, 07/05/2011 -- 09/30/2012
 
Delivery of a bacterial inhibitor of NF-kB to colon tumors
Hardwidge, Philip R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R03CA155868-03), $66,659USD, 07/05/2011 -- 06/30/2014
 
Reverse vaccinology of enterotoxigenic E. coli
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 7R21AI092266-02), $187,500USD, 08/01/2012 -- 07/31/2014
2011
Bacterial effector inhibition of type I interferon
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R21AI093913-01), $187,500USD, 03/01/2011 -- 02/28/2013
 
Bacterial effector subversion of host protein trafficking
Hardwidge, Philip R
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R03AI087923-02), $74,250USD, 02/15/2010 -- 01/31/2013
 
Delivery of a bacterial inhibitor of NF-kB to colon tumors
Hardwidge, Philip R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R03CA155868-01A1), $75,000USD, 07/05/2011 -- 06/30/2013